TD Cowen Starts Halozyme Therapeutics (HALO) at Outperform, 'I Can See Your Halo…But I Never Really Had A Doubt'
Tweet Send to a Friend
TD Cowen analyst Brendan Smith initiates coverage on Halozyme Therapeutics (NASDAQ: HALO) with a Outperform rating and a price target ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
